Clinical Trial Update: Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates doravirine in HIV-infected children aged 4 weeks to under 12 years and weighing less than 45 kg; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Doravirine (doravirine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus (HIV) Infection | Phase 2 | Status: RECRUITING